Pavinetant

Pavinetant

Clinical data
Other names	MLE-4901; AZD-4901; AZD-2624; AZ-12472520
Routes of administration	By mouth
Identifiers
IUPAC name 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
CAS Number	941690-55-7
PubChem CID	23649245
ChemSpider	28189763
UNII	3U471ZVC5K
KEGG	D11345
ChEBI	CHEBI:140478
ChEMBL	ChEMBL3545233
CompTox Dashboard (EPA)	DTXSID10916204
Chemical and physical data
Formula	C26H25N3O3S
Molar mass	459.56 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@@H](C1=CC=CC=C1)NC(=O)C2=C(C(=NC3=CC=CC=C32)C4=CC=CC=C4)NS(=O)(=O)C
InChI InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1 Key:QYTBBBAHNIWFOD-NRFANRHFSA-N

Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK₃) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.

See also

• Tachykinin receptor 3 § Agonists

External links

• Pavinetant - AdisInsight